{
    "title": "112_hr2746",
    "content": "The \"Cancer Drug Coverage Parity Act of 2011\" is also known as the \"Parity in Coverage for Oral Anticancer Drugs\" Act. It amends the Employee Retirement Income Security Act of 1974 to ensure equal coverage for oral anticancer drugs. The Cancer Drug Coverage Parity Act of 2011, also known as the Parity in Coverage for Oral Anticancer Drugs Act, requires group health plans and health insurance issuers to provide equal coverage for orally administered anticancer medication approved by the FDA, prescribed based on medical necessity and clinical appropriateness. The Cancer Drug Coverage Parity Act of 2011 mandates equal coverage for orally administered anticancer medication prescribed based on medical necessity and clinical appropriateness. Coverage may include deductibles and coinsurance, but cannot exceed those for intravenously administered anticancer medications. The Cancer Drug Coverage Parity Act of 2011 prohibits the issuer from increasing out-of-pocket costs or reclassifying benefits for anticancer medications. The provisions of subsections (b), (c), (d), and (e)(2) of section 713 apply to the coverage required by the Act, with January 1, 2012, as the effective date. The Act does not mandate the use of orally administered anticancer medications as a replacement for other forms. The Cancer Drug Coverage Parity Act of 2011 prohibits health plans from imposing utilization controls on chemotherapy coverage. Amendments are made to sections 731(c) and 732(a) of the Act. The Cancer Drug Coverage Parity Act of 2011 prohibits health plans from imposing utilization controls on chemotherapy coverage. Amendments are made to ensure parity in coverage for oral anticancer drugs. The Cancer Drug Coverage Parity Act of 2011 mandates equal coverage for orally administered anticancer medication approved by the FDA, as intravenously administered anticancer medications. This coverage applies only when prescribed by a physician based on medical necessity and clinical appropriateness. The Cancer Drug Coverage Parity Act of 2011 requires equal coverage for oral anticancer medication as intravenous ones, based on medical necessity. Coverage may include deductibles and coinsurance, but cannot increase out-of-pocket costs for patients. The Cancer Drug Coverage Parity Act of 2011 mandates equal coverage for oral anticancer medication as intravenous ones, without increasing out-of-pocket costs for patients. The Act also applies certain provisions of the Employee Retirement and Income Security Act of 1974 to ensure compliance with the coverage requirements. The Cancer Drug Coverage Parity Act of 2011 ensures equal coverage for oral and intravenous anticancer medication, without raising patient costs. Amendments to various sections of the Public Health Service Act and Internal Revenue Code are made to enforce coverage requirements. Amendments to the Internal Revenue Code of 1986 are made to enforce coverage requirements for cancer drug parity. Amendments to the Internal Revenue Code of 1986 enforce coverage requirements for cancer drug parity, including SEC. 9816 on parity in coverage for oral anticancer drugs. Group health plans must provide equal coverage for orally administered anticancer medication approved by the FDA, as they do for intravenously administered or injected anticancer medications. This coverage is subject to certain limitations, including medical necessity, clinical appropriateness, and not being primarily for the patient's convenience. The coverage of anticancer medication under group health plans may be subject to deductibles and coinsurance, as long as they do not exceed those for intravenously administered medications. Plans cannot increase out-of-pocket costs or reclassify benefits for anticancer medications to comply with the requirements. The provisions of the Employee Retirement and Income Security Act of 1974 apply to the coverage of orally administered anticancer medications, with certain exceptions. Group health plans can still require prior authorization for chemotherapy coverage. The Employee Retirement and Income Security Act of 1974 applies to coverage of orally administered anticancer medications, allowing group health plans to require prior authorization for chemotherapy coverage. Appropriate utilization controls are necessary in approving coverage for any chemotherapy. Section 9815 introduces additional market reforms, while Section 9816 focuses on parity in coverage for oral anticancer drugs. The effective date for these amendments is for group health plans starting on or after January 1, 2012. After January 1, 2012, health insurance coverage in the individual market will be studied by the Medicare Payment Advisory Commission to assess the impact of closing the Medicare part D donut hole on coverage for orally administered anticancer medications, focusing on cost and accessibility. A report will be submitted to Congress on the study's results."
}